- Title: Subtitle
- Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP)
- Creators
- Carryn M. Anderson - University of IowaChristopher M Lee - Cancer Care NorthwestDeborah Saunders - Northeast Cancer CentreAmarinthia Curtis - Spartanburg Regional Medical CenterNeal Dunlap - University of LouisvilleChaitali Singh Nangia - OrangeArielle Shebay Lee - HOPE Cancer Center of East Texas, Tyler, TX;Jon Holmlund - Galera Therapeutics, Inc, Malvern, PA;Jeffrey Mark Brill - Galera Therapeutics, Inc, Malvern, PA;Stephen T. Sonis - BioModels, Boston, MA;John Michael Buatti - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.36(15_suppl), pp.6006-6006
- DOI
- 10.1200/JCO.2018.36.15_suppl.6006
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2018
- Academic Unit
- Neurosurgery; Otolaryngology; Radiation Oncology
- Record Identifier
- 9984315650402771
Abstract
Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP)
Journal of clinical oncology, Vol.36(15_suppl), pp.6006-6006
05/20/2018
DOI: 10.1200/JCO.2018.36.15_suppl.6006
Details
Metrics
1 Record Views